| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| Trevi Therapeutics, Inc. | Chief Commercial Officer | Common Stock | 76.9K | $550K | $7.15 | Mar 10, 2025 | Direct |
| Trevi Therapeutics, Inc. | Chief Commercial Officer | Performance Stock Option (right to buy) | 110K | May 31, 2025 | Direct | ||
| Trevi Therapeutics, Inc. | Chief Commercial Officer | Stock Option (right to buy) | 18.8K | Mar 10, 2025 | Direct |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| TRVI | Trevi Therapeutics, Inc. | May 31, 2025 | 1 | $0 | 4 | Jun 3, 2025 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Mar 10, 2025 | 9 | -$227K | 4 | Mar 12, 2025 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 18, 2025 | 1 | $0 | 4 | Feb 20, 2025 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 15, 2024 | 1 | $0 | 4 | Feb 16, 2024 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Jun 20, 2023 | 2 | $3.19K | 4 | Jun 21, 2023 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Mar 7, 2023 | 2 | $9.58K | 4 | Mar 8, 2023 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 16, 2023 | 1 | $0 | 4 | Feb 16, 2023 | Chief Commercial Officer |
| TRVI | Trevi Therapeutics, Inc. | Feb 16, 2023 | 0 | $0 | 3 | Feb 16, 2023 | Chief Commercial Officer |